Baxter International’s stock narrative has seen an important update following the latest guidance and financial results. While analysts have maintained their consensus fair value per share at $24.07, the discount rate used in valuation models has risen slightly, from 9.73% to 10.00%. This change reflects a modest increase in perceived risk or cost of capital. Stay tuned to discover how investors can best keep up with evolving perspectives on Baxter’s value drivers and outlook.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Baxter International.

???? Bullish Takeaways

While commentary from the reviewed analysts remains mostly reserved, there is recognition that Baxter's management has taken steps to mitigate margin pressures through reductions in R&D and SG&A spending, partially offsetting operational headwinds.

The company has maintained transparency around business pressures and near-term guidance, which may help set realistic expectations among investors.

Some analysts note experienced new leadership and the ongoing adjustments signal a proactive approach. This could support incremental improvements over a longer horizon.

???? Bearish Takeaways

Goldman Sachs, through analyst David Roman, lowered its price target for Baxter International to $22 from $25, citing disappointing Q3 results and ongoing revenue shortfalls, particularly in the MPT and Pharma segments.

Gross margins declined sharply to 39.4%, with manufacturing variances expected to keep pressure on margins into 2026.

Reduced FY25 organic growth and EPS guidance points to persistent near-term softness and limited visibility into 2026 earnings. Forecasted headwinds are outweighing any expected tailwinds.

Stifel also cut its price target to $22 from $25, maintaining a Hold rating. The firm attributed the reduced outlook to continued business pressures and recent management changes, describing Q3’s performance as "clearly disappointing."

Bears are emphasizing the risk that ongoing operational and market headwinds may constrain both valuation and growth momentum in the coming quarters.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Baxter International's Board of Directors has declared a quarterly cash dividend of $0.01 per share, with an annualized rate of $0.04 per share. The dividend is scheduled for payment on January 2, 2026, to stockholders of record as of November 28, 2025.

The company completed a significant share repurchase, buying back more than 103 million shares. This represents nearly 20% of its outstanding shares and totals $7.2 billion under its ongoing buyback program.

Baxter issued new earnings guidance for the fourth quarter and full year 2025. The company anticipates reported sales growth of 2% in Q4 and 4% to 5% for the year from continuing operations.

A securities class action lawsuit has been filed against Baxter International and certain executives. The lawsuit alleges that misleading statements were made regarding safety and sales prospects of the Novum LVP infusion pump, after injury reports led to a voluntary shipping pause and a substantial fall in the company’s share price.

The discount rate has risen slightly from 9.73% to 10.00%, reflecting a marginal increase in risk or cost of capital assumptions.

Consensus analyst fair value remains unchanged at $24.07 per share. This indicates no adjustment in long-term intrinsic value estimates.

Revenue growth projections are unchanged at 1.75%.

Net profit margin has remained steady at 6.57%.

The future P/E ratio has increased modestly from 21.85x to 21.89x, which suggests a minor upward revision to earnings multiple expectations.

Narratives turn complex numbers into a story you can actually use. A Narrative connects a company’s unique journey with real financial forecasts and a fair value, making investing easier to understand and act on. On Simply Wall St’s Community page, millions of investors use Narratives to decide when to buy or sell by comparing Fair Value to share price. Best of all, Narratives stay current and are updated any time key news or earnings arrive.

Head over to the original Narrative for Baxter International and stay updated on:

How Baxter’s hospital business and innovation efforts could drive a rebound in revenue and margins as market conditions normalize.

The impact of new leadership and ongoing cost reductions on future efficiency and long-term earnings growth.

Real-time risks and catalysts, including guidance revisions and product updates, that shape where Baxter’s fair value goes next.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BAX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com